ABBV : Summary for AbbVie Inc. Common Stock - Yahoo Finance

U.S. Markets closed

AbbVie Inc. (ABBV)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
61.77+0.29 (+0.47%)
At close: 4:01PM EST
People also watch
ABTGILDCELGBMYBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close61.48
Open61.54
Bid0.00 x
Ask0.00 x
Day's Range61.17 - 62.08
52 Week Range53.74 - 68.12
Volume8,124,442
Avg. Volume7,239,416
Market Cap100.38B
Beta1.47
PE Ratio (TTM)17.02
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.56 (4.14%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
    Zacks2 days ago

    Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

    Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

  • PR Newswire2 days ago

    AbbVie Announces $5 Billion Increase to Stock Repurchase Program

    NORTH CHICAGO, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.

  • Investopedia3 days ago

    NICE Rejects AbbVie’s Leukemia Drug Venclexta

    Venclexta, which was approved in the US, was rejected by the UK public health watchdog, NICE.